Kiora Pharmaceuticals Inc. (KPRX) Stock Price, Quote & News

Company Profile

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydr...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 224 9600

Website: www.kiorapharma.com

Address:

332 Encinitas Boulevard, Suite 102, Encinitas, United States

justiceforb_85 May. 25 at 8:17 PM

$KPRX science behind KIO-301 is fascinating in RP and will likely work in choroideremia. Finances seem precarious though. Any bulls in here?

0 · Reply

OnlyFibs May. 24 at 8:26 PM

$KPRX has spent weeks carving out a massive base, and the volume profile shows a heavy node right where we are currently trading. If the buyers can chew through this final layer of resistance, the overhead structure looks incredibly thin for a momentum run. 🚀🔬 🐂 Bull Level: A weekly close over $2.58 unlocks the expansion lane toward $2.78+. 🐻 Bear Level: Rejection at resistance puts $2.41 in the crosshairs. Lose that, and the bottom-fishing thesis is dead. 🛑 #SwingTrading #Momentum #StockMarket #KPRX #hovdid

0 · Reply